The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.
 
Carlos Fernandez-Martos
Consulting or Advisory Role - Amgen
Research Funding - Amgen; SANOFI
Travel, Accommodations, Expenses - Amgen; Roche
 
Jorge Aparicio
Consulting or Advisory Role - Amgen; Bayer; Merck
 
Juan Ayuso
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
 
Javier Gallego
Consulting or Advisory Role - Amgen
 
Ferran Losa
No Relationships to Disclose
 
Monique Maas
No Relationships to Disclose
 
Joan Maurel
No Relationships to Disclose
 
Carles Pericay
No Relationships to Disclose
 
Nuria Rodriguez Salas
No Relationships to Disclose
 
Maria Jose Safont
Consulting or Advisory Role - Amgen; Bayer; Merck; Roche; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Merck; Taiho Pharmaceutical
 
Maria Tobeña
No Relationships to Disclose
 
Manuel Valladares
Consulting or Advisory Role - Amgen
Research Funding - Amgen; Roche
Travel, Accommodations, Expenses - Amgen
 
Ruth Vera
No Relationships to Disclose